

IQCF6 (W-13): sc-102721

BACKGROUND

Chromosome 3 is made up of about 214 million bases encoding over 1,100 genes. Notably, there is a chemokine receptor gene cluster and a variety of human cancer related loci on chromosome 3. Particular regions of the chromosome 3 short arm are deleted in many types of cancer cells. Key tumor suppressing genes on chromosome 3 encode apoptosis mediator RASSF1, cell migration regulator HYAL1 and angiogenesis suppressor SEMA3B. Marfan syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth disease are a few of the numerous genetic diseases associated with chromosome 3. The IQCF6 gene product has been provisionally designated IQCF6 pending further characterization.

REFERENCES

1. Müller, S., et al. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. *Proc. Natl. Acad. Sci. USA* 97: 206-211.
2. Braga, E.A., et al. 2003. New tumor suppressor genes in hot spots of human chromosome 3: new methods of identification. *Mol. Biol.* 37: 194-211.
3. Tsend-Ayush, E., et al. 2004. Plasticity of human chromosome 3 during primate evolution. *Genomics* 83: 193-202.
4. Darai, E., et al. 2005. Evolutionarily plastic regions at human 3p21.3 coincide with tumor breakpoints identified by the "elimination test". *Genomics* 86: 1-12.
5. Yue, Y., et al. 2005. Genomic structure and paralogous regions of the inversion breakpoint occurring between human chromosome 3p12.3 and orangutan chromosome 2. *Cytogenet. Genome Res.* 108: 98-105.
6. Yue, Y., et al. 2005. Comparative cytogenetics of human chromosome 3q21.3 reveals a hot spot for ectopic recombination in hominoid evolution. *Genomics* 85: 36-47.
7. Muzny, D.M., et al. 2006. The DNA sequence, annotation and analysis of human chromosome 3. *Nature* 440: 1194-1198.
8. Nareyck, G., et al. 2006. Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3. *Exp. Eye Res.* 83: 858-864.

CHROMOSOMAL LOCATION

Genetic locus: IQCF6 (human) mapping to 3p21.2.

SOURCE

IQCF6 (W-13) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of IQCF6 of human origin.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-102721 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

IQCF6 (W-13) is recommended for detection of IQCF6 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IQCF6 siRNA (h): sc-77943, IQCF6 shRNA Plasmid (h): sc-77943-SH and IQCF6 shRNA (h) Lentiviral Particles: sc-77943-V.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.